Computational design of peptides to target NaV1.7 channel with high potency and selectivity for the treatment of pain

  1. Phuong T Nguyen
  2. Hai M Nguyen
  3. Karen M Wagner
  4. Robert Stewart
  5. Vikrant Singh
  6. Parashar Thapa
  7. Yi-Je Chen
  8. Mark W Lillya
  9. Anh Tuan Ton
  10. Richard Kondo
  11. Andre Ghetti
  12. Michael W Pennington
  13. Bruce Hammock
  14. Theanne N Griffith
  15. Jon T Sack
  16. Heike Wulff  Is a corresponding author
  17. Vladimir Yarov-Yarovoy  Is a corresponding author
  1. University of California, Davis, United States
  2. University of California Davis Medical Center, United States
  3. AnaBios, United States
  4. AmbioPharm Inc, United States

Abstract

The voltage-gated sodium NaV1.7 channel plays a key role as a mediator of action potential propagation in C-fiber nociceptors and is an established molecular target for pain therapy. ProTx-II is a potent and moderately selective peptide toxin from tarantula venom that inhibits human NaV1.7 activation. Here we used available structural and experimental data to guide Rosetta design of potent and selective ProTx-II-based peptide inhibitors of human NaV1.7 channels. Functional testing of designed peptides using electrophysiology identified the PTx2-3127 and PTx2-3258 peptides with IC50s of 7 nM and 4 nM for hNaV1.7 and more than 1,000-fold selectivity over human NaV1.1, NaV1.3, NaV1.4, NaV1.5, NaV1.8, and NaV1.9 channels. PTx2-3127 inhibits NaV1.7 currents in mouse and human sensory neurons and shows efficacy in rat models of chronic and thermal pain when administered intrathecally. Rationally-designed peptide inhibitors of human NaV1.7 channels have transformative potential to define a new class of biologics to treat pain.

Data availability

All data generated or analysed during this study are included in the manuscript.

Article and author information

Author details

  1. Phuong T Nguyen

    Department of Physiology and Membrane Biology, University of California, Davis, Davis, United States
    Competing interests
    Phuong T Nguyen, is named inventor on a patent application entitled 'Peptides targeting sodium channels to treat pain' based on this research, filed by the University of California.(U.S. provisionalapplication no. 63/358,684, filed July 6, 2022)..
  2. Hai M Nguyen

    Department of Pharmacology, University of California, Davis, Davis, United States
    Competing interests
    Hai M Nguyen, is named inventor on a patent application entitled 'Peptides targeting sodium channels to treat pain' based on this research, filed by the University of California. (U.S. provisionalapplication no. 63/358,684, filed July 6, 2022)..
  3. Karen M Wagner

    Department of Entomology and Nematology, University of California, Davis, Davis, United States
    Competing interests
    Karen M Wagner, is named inventor on a patent application entitled 'Peptides targeting sodium channels to treat pain' based on this research, filed by the University of California. (U.S. provisionalapplication no. 63/358,684, filed July 6, 2022)..
  4. Robert Stewart

    Department of Physiology and Membrane Biology, University of California, Davis, Davis, United States
    Competing interests
    No competing interests declared.
  5. Vikrant Singh

    Department of Pharmacology, University of California, Davis, Davis, United States
    Competing interests
    No competing interests declared.
  6. Parashar Thapa

    Department of Physiology and Membrane Biology, University of California, Davis, Davis, United States
    Competing interests
    No competing interests declared.
  7. Yi-Je Chen

    Department of Pharmacology, University of California, Davis, Davis, United States
    Competing interests
    No competing interests declared.
  8. Mark W Lillya

    Department of Physiology and Membrane Biology, University of California Davis Medical Center, Davis, United States
    Competing interests
    No competing interests declared.
  9. Anh Tuan Ton

    AnaBios, San Diego, United States
    Competing interests
    Anh Tuan Ton, is affiliated with AnaBios Corporation. The author has no financial interests to declare..
  10. Richard Kondo

    AnaBios, San Diego, United States
    Competing interests
    Richard Kondo, is affiliated with AnaBios Corporation. The author has no financial interests to declare..
  11. Andre Ghetti

    AnaBios, San Diego, United States
    Competing interests
    Andre Ghetti, is affiliated with AnaBios Corporation. The author has no financial interests to declare..
  12. Michael W Pennington

    AmbioPharm Inc, North Augusta, United States
    Competing interests
    Michael W Pennington, is affiliated with Ambiopharm Inc. The author has no financial interests to declare..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5446-3447
  13. Bruce Hammock

    Department of Entomology and Nematology, University of California, Davis, Davis, United States
    Competing interests
    Bruce Hammock, is named inventor on a patent application entitled 'Peptides targeting sodium channels to treat pain' based on this research, filed by the University of California. (U.S. provisionalapplication no. 63/358,684, filed July 6, 2022)..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1408-8317
  14. Theanne N Griffith

    Department of Physiology and Membrane Biology, University of California, Davis, Davis, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0090-6286
  15. Jon T Sack

    Department of Physiology and Membrane Biology, University of California, Davis, Davis, United States
    Competing interests
    Jon T Sack, Reviewing editor, eLife.Is named inventor on a patent application entitled 'Peptides targeting sodium channels to treat pain' based on this research, filed by the application no. 63/358,684, filed July 6, 2022)..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6975-982X
  16. Heike Wulff

    Department of Pharmacology, University of California, Davis, Davis, United States
    For correspondence
    hwulff@ucdavis.edu
    Competing interests
    Heike Wulff, is named inventor on a patent application entitled 'Peptides targeting sodium channels to treat pain' based on this research, filed by the University of California. (U.S. provisionalapplication no. 63/358,684, filed July 6, 2022)..
  17. Vladimir Yarov-Yarovoy

    Department of Physiology and Membrane Biology, University of California, Davis, Davis, United States
    For correspondence
    yarovoy@ucdavis.edu
    Competing interests
    Vladimir Yarov-Yarovoy, is named inventor on a patent application entitled 'Peptides targeting sodium channels to treat pain' based on this research, filed by the University of California. (U.S. provisionalapplication no. 63/358,684, filed July 6, 2022)..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2325-4834

Funding

National Institute of Neurological Disorders and Stroke (UG3NS114956)

  • Phuong T Nguyen
  • Hai M Nguyen
  • Karen M Wagner
  • Robert Stewart
  • Vikrant Singh
  • Parashar Thapa
  • Yi-Je Chen
  • Mark W Lillya
  • Anh Tuan Ton
  • Richard Kondo
  • Andre Ghetti
  • Michael W Pennington
  • Bruce Hammock
  • Theanne N Griffith
  • Jon T Sack
  • Heike Wulff
  • Vladimir Yarov-Yarovoy

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: Research involving vertebrate animals was done at the University of California following protocols reviewed and approved by the UC Davis Institutional Animal Care and Use Committee (UCD IACUC) - Animal Welfare Assurance Number A3433-01. The animals were cared for by the Center for Laboratory Animal Science (CLAS) Veterinary Services under a currently AAALAC approved program under the direction of Dr. Laura Brignolo (Campus Veterinarian). The animals were housed in NIH-approved facilities in CLAS and are observed daily by technicians. Unusual events are reported to the on call veterinarian, as well as to the investigator according to posted protocols. Other maintenance veterinary care was conducted according to NIH guidelines on the Use and Care of Animals. Facilities were inspected regularly according to NIH and AAALAC guidelines.

Copyright

© 2022, Nguyen et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,382
    views
  • 454
    downloads
  • 16
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Phuong T Nguyen
  2. Hai M Nguyen
  3. Karen M Wagner
  4. Robert Stewart
  5. Vikrant Singh
  6. Parashar Thapa
  7. Yi-Je Chen
  8. Mark W Lillya
  9. Anh Tuan Ton
  10. Richard Kondo
  11. Andre Ghetti
  12. Michael W Pennington
  13. Bruce Hammock
  14. Theanne N Griffith
  15. Jon T Sack
  16. Heike Wulff
  17. Vladimir Yarov-Yarovoy
(2022)
Computational design of peptides to target NaV1.7 channel with high potency and selectivity for the treatment of pain
eLife 11:e81727.
https://doi.org/10.7554/eLife.81727

Share this article

https://doi.org/10.7554/eLife.81727

Further reading

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Cristina Paissoni, Sarita Puri ... Carlo Camilloni
    Research Article

    Both immunoglobulin light-chain (LC) amyloidosis (AL) and multiple myeloma (MM) share the overproduction of a clonal LC. However, while LCs in MM remain soluble in circulation, AL LCs misfold into toxic-soluble species and amyloid fibrils that accumulate in organs, leading to distinct clinical manifestations. The significant sequence variability of LCs has hindered the understanding of the mechanisms driving LC aggregation. Nevertheless, emerging biochemical properties, including dimer stability, conformational dynamics, and proteolysis susceptibility, distinguish AL LCs from those in MM under native conditions. This study aimed to identify a2 conformational fingerprint distinguishing AL from MM LCs. Using small-angle X-ray scattering (SAXS) under native conditions, we analyzed four AL and two MM LCs. We observed that AL LCs exhibited a slightly larger radius of gyration and greater deviations from X-ray crystallography-determined or predicted structures, reflecting enhanced conformational dynamics. SAXS data, integrated with molecular dynamics simulations, revealed a conformational ensemble where LCs adopt multiple states, with variable and constant domains either bent or straight. AL LCs displayed a distinct, low-populated, straight conformation (termed H state), which maximized solvent accessibility at the interface between constant and variable domains. Hydrogen-deuterium exchange mass spectrometry experimentally validated this H state. These findings reconcile diverse experimental observations and provide a precise structural target for future drug design efforts.

    1. Structural Biology and Molecular Biophysics
    Kingsley Y Wu, Ta I Hung, Chia-en A Chang
    Research Article

    PROteolysis TArgeting Chimeras (PROTACs) are small molecules that induce target protein degradation via the ubiquitin-proteasome system. PROTACs recruit the target protein and E3 ligase; a critical first step is forming a ternary complex. However, while the formation of a ternary complex is crucial, it may not always guarantee successful protein degradation. The dynamics of the PROTAC-induced degradation complex play a key role in ubiquitination and subsequent degradation. In this study, we computationally modelled protein complex structures and dynamics associated with a series of PROTACs featuring different linkers to investigate why these PROTACs, all of which formed ternary complexes with Cereblon (CRBN) E3 ligase and the target protein bromodomain-containing protein 4 (BRD4BD1), exhibited varying degrees of degradation potency. We constructed the degradation machinery complexes with Culling-Ring Ligase 4A (CRL4A) E3 ligase scaffolds. Through atomistic molecular dynamics simulations, we illustrated how PROTAC-dependent protein dynamics facilitating the arrangement of surface lysine residues of BRD4BD1 into the catalytic pocket of E2/ubiquitin cascade for ubiquitination. Despite featuring identical warheads in this PROTAC series, the linkers were found to affect the residue-interaction networks, and thus governing the essential motions of the entire degradation machine for ubiquitination. These findings offer a structural dynamic perspective on ligand-induced protein degradation, providing insights to guide future PROTAC design endeavors.